AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CRISPR Therapeutics AG Director's Dealing 2016

Oct 18, 2016

30936_dirs_2016-10-18_7e4d7bab-b6cf-484c-b315-e1d687d778e4.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2016-10-18

Reporting Person: COLES N ANTHONY (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Options (Right to Buy)	$1.81	2025-09-10	Common Shares (217827)		Direct
Stock Options (Right to Buy)	$1.81	2025-09-10	Common Shares (50266)		Indirect

Footnotes

F1: This option was granted on September 10, 2015 with respect to 217,827 Common Shares with 100% of the shares vesting in 48 equal monthly installments thereafter.

F2: This option was granted on September 10, 2015 with respect to 50,266 Common Shares with 100% of the shares vesting in 48 equal monthly installments thereafter.